Mivavotinib

Overview

TAK-659 is a highly potent, selective, reversible and orally available dual inhibitor of spleen tyrosine kinase ( SYK ) and fms related tyrosine kinase 3 ( FLT3 ) , with an IC 50 of 3.2 nM and 4.6 nM for SYK and FLT3 , respectively. TAK-659 induces cell death in tumor cells but not in nontumor cells, and with potential for the treatment of chronic lymphocytic leukemia (CLL).

Application

Products | Products > Signaling Pathways > Protein Tyrosine Kinase/RTK | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Immunotherapy | Products > Signaling Pathways > Syk | Products > Signaling Pathways > FLT3

Product Information

• Catalog No.: HY-100867
• CAS No.: 1312691-33-0
• Molecular Formula: C17H21FN6O
• Molecular Weight: 344.39
• Purity: 99.98%
• Storage: Please store the product under the recommended conditions in the Certificate of Analysis.

Source

Original product source